Please login to the form below

Not currently logged in
Email:
Password:

certolizumab pegol

This page shows the latest certolizumab pegol news and features for those working in and with pharma, biotech and healthcare.

CHMP backs first-line use for AZ’s Tagrisso in lung cancer

CHMP backs first-line use for AZ’s Tagrisso in lung cancer

There were also new indications approved for UCB’s Cimzia (certolizumab pegol), Amgen’s Prolia (denosumab), BMS’ Sprycel (dasatinib) and Yervoy (ipilimumab), Pfizer’s Xeljanz (tofacitinib), and Novo Nordisk’s Xultophy

Latest news

  • NICE approves UCB Pharma’s Cimzia NICE approves UCB Pharma’s Cimzia

    The draft guidance states that Cimzia (certolizumab pegol) can be used on its own or in combination with methotrexate when other drugs have not worked or are not suitable to treat ... We hope that adding certolizumab pegol to this list will mean that

  • NICE set to recommend seven biologics for severe rheumatoid arthritis NICE set to recommend seven biologics for severe rheumatoid arthritis

    NICE's other new final draft recommendations for severe RA also include AbbVie's Humira (adalimumab), Pfizer's Enbrel (etanercept), UCB Pharma's Cimzia (certolizumab pegol), Merck Sharp &Dohme's Simponi

  • UCB boosted by core medicines growth UCB boosted by core medicines growth

    Revenue was boosted by its core product range, with Crohn's disease and psoriatic arthritis treatment Cimzia (certolizumab pegol); epilepsy medicine Vimpat (lacosamide) and Parkinson's disease and restless leg syndrome

  • NICE backs biosimilars in rheumatoid arthritis guidance NICE backs biosimilars in rheumatoid arthritis guidance

    The recommended brands are: AbbVie's Humira (adalimumab), Pfizer's Enbrel (etanercept), UCB's Cimzia (certolizumab pegol), MSD/Johnson &Johnson's Simponi (golimumab), Roche's RoActemra (tocilizumab), Bristol-Myers Squibb's

  • UCB moves Cimzia into phase III trials for psoriasis UCB moves Cimzia into phase III trials for psoriasis

    Cimzia (certolizumab pegol) received FDA approval for its use in patients with psoriatic arthritis in late 2013, in addition to existing licences for rheumatoid arthritis and Crohn's disease, but it

More from news
Approximately 2 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • Deal Watch table for July 2014 Deal Watch table for July 2014

    107. UCB/ Dermira. Licence ††. Cimzia (certolizumab pegol) - drug repurposing (p2 for psoriasis).

  • VIDEO interview: Neil Weir, UCB VIDEO interview: Neil Weir, UCB

    For UCB, this notion is especially important considering its focus on severe diseases, including the recent launches of Cimzia (certolizumab pegol) for rheumatoid arthritis and Crohn's disease; Vimpat (lacosamide) for

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full-service agency with a clear focus on delivering evidence-based, sustained behaviour change. So, whether you are looking...

Latest intelligence

Language barriers: Obesity has become a loaded word
...
Spotlight interview: 15 minutes on digital in medical communications
Gemma Allen, Head of Digital Communications, OPEN Health takes 15 minutes to answer some key questions on digital in medical communications...
Generating data on long-term outcomes with gene and other advanced therapies
Gene therapy and advanced cell-based therapies offer patients hope and the potential to make them ‘chronically well’....

Infographics